Shares of Onyx Pharmaceuticals Inc. shot up 21 percent on top-line results showing that its multikinase inhibitor Nexavar met the primary endpoint in a Phase II trial, extending progression-free survival in breast cancer patients taking Xeloda. (BioWorld Today) Read More
